Cholangiocarcinoma (Bile Duct Cancer) Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Cholangiocarcinoma (Bile Duct Cancer).
Found 3 Approved Drugs for Cholangiocarcinoma (Bile Duct Cancer)
Pemazyre
Generic Name
Pemigatinib
Pemazyre
Generic Name
Pemigatinib
Form: Tablet
Method of administration: Oral
FDA approval date: April 17, 2020
Classification: Kinase Inhibitor
PEMAZYRE is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. ( 1.
Tibsovo
Generic Name
Ivosidenib
Tibsovo
Generic Name
Ivosidenib
Form: Tablet
Method of administration: Oral
FDA approval date: October 19, 2021
Classification: Isocitrate Dehydrogenase 1 Inhibitor
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Lytgobi
Generic Name
Futibatinib
Lytgobi
Generic Name
Futibatinib
Form: Tablet
Method of administration: Oral
FDA approval date: February 03, 2023
Classification: Kinase Inhibitor
LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements [see Dosage and Administration.
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances